- Economic burden of follicular non-Hodgkin's lymphomaTalia Foster
Abt Bio Pharma Solutions, Inc, Lexington, Massachusetts, USA
Pharmacoeconomics 27:657-79. 2009..As new treatments for FNHL come to market, more real-life cost data are imperative to calculate their relative cost effectiveness...
- Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspectiveNandini Hadker
Abt Bio Pharma Solutions, Inc, Lexington, MA 02420, USA
J Med Econ 13:728-37. 2010..Early diagnosis may be possible with a new serum test, with resulting clinical and economic benefits versus standard practice. The authors evaluated the financial impact to the UK National Health Service (NHS)...
- Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) dataJeffrey D Miller
Boston Health Economics, Inc, 20 Fox Road, Waltham, Massachusetts 02451, USA
COPD 2:311-8. 2005..Results of our study indicate that COPD-associated healthcare utilization and expenditures are considerable, and that annual per-patient costs of COPD are comparable to those of other chronic diseases of the middle-aged and elderly...
- Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic reviewLindsay Hallett
United BioSource Corporation, Lexington, MA, USA
Curr Med Res Opin 27:1571-83. 2011..Tuberous sclerosis complex (TSC) is a progressive genetic disorder characterized by pervasive benign tumor growth. We sought to assess the current understanding of burden of TSC-related neurological manifestations...